Centre for Genomics of Non-Communicable Diseases and Personalized Healthcare (CGNPH)

Creating a hub for advanced basic, clinical and epidemiological genomic training, innovation and research on non-communicable diseases across the African region through strategic partnership and collaboration

At CGNPH, our Molecular Endocrinology and Oncology Genomics initiative focuses on the interplay between hormonal imbalances and cancer development. Utilizing advanced genomic technologies, we aim to identify unique biomarkers for early cancer detection and precision treatment, blending endocrinology with oncology to enhance diagnosis and care. This approach propels personalized medicine forward, offering targeted therapies based on individual genetic profiles.

At CGNPH, we seek to stimulate innovative and impactful research that explores novel biomarkers and genomic variants associated with the development and progression of cardiovascular and cardiometabolic diseases across the lifespan in cohorts with chronic diseases; and to explore markers for risk prediction and stratification, disease diagnosis and prognostication and personalized treatment. Also of research interest is the role of micronutrients in the aetiogenesis and modulation of cardiovascular and cardiometabolic diseases across the lifespan.The fetal origins hypothesis of CVDs and the impact of intrauterine growth on developmental adaptations that program vulnerability to cardiovascular and cardiometabolic diseases later in life constitute an important part of our program.

Pharmacogenomics studies variations in the genetic make-up of an individual and relates this to drug response. The benefits of minimizing the risk of toxicity and increasing effectiveness are the key drivers of personalized medicine. At CGNPH, we aim to understand germline genetic variations that are present within our community by adopting a candidate gene approach and thereby address the lack of pharmacogenomic data as regards the therapy of non-communicable diseases.

Metabolic syndrome is a multifactorial disease condition defined by a clustering of risk factors including hypertension, insulin resistance, and obesity. This clustering of risk factors predisposes an individual to an increased risk for diabetes and cardiovascular disease. Genomic studies are beginning to show a number of overlapping genes and polymorphisms that influence both the development of diabetes and Metabolic syndrome. At CGNPH, we are committed to providing genomic research data that will help revolutionize the screening, diagnosis and management of metabolic syndrome and diabetes with a view to ensuring personalized (tailored) health care to individual’s need.

The combine effect of non-communicable (NCDs) and communicable diseases is contributing enormously to the shorter life span experienced globally by individual with such comorbidity. The fatality in people with hypertension and type 2 diabetes mellitus is increasing with infectious diseases like HIV and Tuberculosis. Covid-19 pandemic has proved this hypothesis to be true because most fatality during the 2019–2021 pandemic are among individuals with such comorbidity. This non-communicable and communicable interfaces thematic group is designed to bridge the gap using genomics and molecular biology technology to study the impact of combine effect of non-communicable and communicable disease, in order to provide mitigation and drug target to alleviate more patients care management.

At CGNPH, our research in the Genomics of Mental Health and Neuroendocrinology aims to unravel the complex genetic and neurobiological underpinnings of mental health disorders. By integrating genomics with neuroendocrinology, we seek to understand how genetic variations and hormonal changes impact mental health, influencing stress response, mood, behavior, and cognition. Our goal is to leverage this knowledge to develop innovative, personalized interventions and treatments that address the root causes of mental health conditions, improving patient outcomes and enhancing the quality of care in mental health services.

Point-of-Care Testing (POCT) is essential for the rapid detection of analytes near to the patient, which facilitates better disease diagnosis, monitoring, and management. At CGNPH, our R&D; applies artificial intelligence, Big Data and Machine Learning Techniques to provide better and personalized healthcare.We focus on developing from innovation through to commercialization, effective and affordable in-vitro POCT devices targeted at NCDs for low-income economies especially in Africa. We co-innovate with industrial partners to deliver better healthcare products and services.

The AI and Data Analytics team at CGNPH focuses on harnessing the power of artificial intelligence and big data analytics to understand the genomic underpinnings of non-communicable diseases. This includes developing predictive models to identify at-risk populations, optimize personalized treatment plans, and advance precision medicine. By analyzing large datasets, including genomic information, lifestyle factors, and environmental exposures, this thematic research will uncover novel insights into disease mechanisms, improve diagnostic accuracy, and enhance patient outcomes through tailored healthcare solutions.

The CGNPH is pioneering research in the Genomics of the Musculoskeletal System and Sports Medicine, focusing on how genetic factors contribute to musculoskeletal health, athletic performance, and the recovery process from sports-related injuries. Our work is dedicated to identifying genetic markers that predict susceptibility to musculoskeletal injuries and their potential for healing, enabling the development of tailored training regimens and rehabilitation programs. This research not only promises to revolutionize the field of sports medicine but also aims to improve the overall management and prevention of musculoskeletal disorders in the broader population.

Our team at CGNPH is at the forefront of integrating Genetics and Nanomedicine to revolutionize Drug Design and Delivery. By exploring the genetic basis of disease alongside cutting-edge nanotechnology, we aim to create highly targeted and efficient drug delivery systems that minimize side effects and enhance therapeutic efficacy. This interdisciplinary approach seeks to usher in a new era of precision medicine where treatments are customized to the genetic makeup of the individual, optimizing patient outcomes and paving the way for breakthroughs in the treatment of complex diseases.

The CGNPH excels in the field of Bioinformatics and Computational Biology, employing advanced computational techniques to analyze and interpret vast amounts of biological data. Our research focuses on developing predictive models and algorithms to uncover the genetic basis of diseases, identify new therapeutic targets, and enhance our understanding of biological processes. By harnessing the power of bioinformatics, we aim to accelerate the pace of discovery in genomics and molecular biology, leading to innovative solutions for disease diagnosis, treatment, and prevention.

At CGNPH, our research into Genomic Vaccines and the Immune System explores the genetic determinants of immune response to develop more effective and personalized vaccines. By analyzing genomic data, we aim to understand the variability in individual immune responses and tailor vaccine development to enhance efficacy and safety. This cutting-edge research not only promises to improve current vaccination strategies but also paves the way for novel genomic-based vaccines to combat emerging infectious diseases and strengthen public health defenses.

From The Director's Desk

The CGNPH is dream to become the premier site for state-of-the-art genomics research and training in NCDs and personalized healthcare in Nigeria and the West African region. This Center is taking advantage being strategically located in Lagos – the industrial gate-way and commercial hub of Nigeria and the West African region – to foster industrial partnerships, multinational and multidisciplinary cooperation with leading academic, healthcare, research, biotechnological, and pharmaceutical institutions and organizations in the public and private sectors within and outside Nigeria who have a track record of enterprise and excellence, toward reducing morbidity and mortality due to NCDs in (West) Africa.

Professor Oluyemi Akinloye

Our vision

To create a hub for advanced basic, clinical and epidemiological genomic training, innovation and research on non-communicable diseases across the African region through strategic partnership and collaboration.

Our mission

To promote the application of genomics in the understanding, prevention, treatment and management of non-communicable diseases through evidence-based research, holistic training, innovative development of tailored drug delivery systems and in-vitro point-of-care medical devices with applied artificial intelligence for personalized healthcare services towards maximizing quality of life of Africans.

Our Objectives

To engage the community and general public about the implications of genomic discoveries and benefits of personalized healthcare services in improving health and informed health-decision-making